Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

May 5, 2022

NASDAQ US Health Care Life Sciences Tools and Services earnings 69 min

Earnings Call Speaker Segments

Sallilyn Schwartz

executive
#1

Hello, everyone, and thanks for joining us this afternoon for our Q1 2022 earnings call. On today's call, we'll go over the financial results that were published after the market closed, and we'll also provide commentary on our commercial activity. After that, we'll hold a question-and-answer session. If you haven't yet looked at the earnings release, you can find it on our website, illumina.com, in the Investor Relations section. With us today from Illumina are Francis deSouza, our President and Chief Executive Officer, and Sam Samad, our Chief Financial Officer. Francis will share an update regarding the state of Illumina's business, and Sam will walk through our financial results, which include GRAIL. As a reminder, while the European Commission's investigation into Illumina's acquisition of GRAIL is pending, the commission has issued an order that requires Illumina and GRAIL to be maintained and run as separate, distinct entities during an interim period. An independent monitoring trustee oversees compliance with this order. Throughout this period, Illumina and GRAIL may not share confidential business information unless legally required, and GRAIL has to operate independently, solely in GRAIL's best interests. Any commercial dealings between the 2 companies must be conducted at arm's length. This call is being recorded, and the audio portion will be archived in the Investors section of our website. We intend for all forward-looking statements about our financial results and commercial activity made on today's call to be protected under the Private Securities Litigation Reform Act of 1995. Forward-looking statements carry risks and uncertainties. Actual events or results could differ materially from those projected or discussed. All forward-looking statements rest on information currently available, and Illumina undertakes no obligation to update these statements. To gain a better understanding of the risks and uncertainties that might cause actual results to differ, please refer to the documents Illumina files with the Securities and Exchange Commission, including Illumina's most recent Forms 10-Q and 10-K. With that, I'll hand the call over to Francis.

Francis deSouza

executive
#2

Thanks, Salli. Hello, everyone, and good afternoon. During Q1, we kept up robust momentum throughout our regions and markets. Oncology, genetic disease testing, and infectious disease all showed notable strength, and we delivered record quarterly results in the Americas and APJ. Before handing things to Sam for further detail, I'll walk through an overview of our results along with what we've achieved across our portfolio and markets. Before starting, I want to express my concern for all those impacted by the war in Ukraine, and we'll keep backing humanitarian efforts to assist the communities affected. Let's begin with the financials. Revenue for Q1 came in at roughly $1.22 billion, up 12% compared with the same period last year; we booked record orders this quarter, with sequencing consumables orders exceeding $1 billion for the first time; and we closed the quarter with a record total backlog, which is a strong leading indicator for the quarters ahead. Now to how our platforms performed. Sequencing instrument shipments rose by over 20% from a year earlier in Q1. We delivered a record quantity of NovaSeqs and booked record NovaSeq consumables orders, reflecting solid demand in the instrument's sixth year on the market as well as growth of our sizable installed base for future consumables revenue. More than half of NovaSeq shipments went to clinical customers, and demand for oncology testing was particularly robust, since high throughput sequencing and comprehensive genomic profiling are playing an ever more essential role in caring for cancer patients. On the mid-throughput front, the number of NextSeq 1000/2000 instruments now installed has surpassed 1,000. Meanwhile, shipments in Q1 of the P1 flow cell, launched in Q4 of 2021, reached roughly double our forecast. New customers, along with those moving toward higher throughput, have embraced the P1 flow cell enthusiastically, and because of its efficiency and cost effectiveness, kit utilization is widespread among current NextSeq 1000/2000 users. Our low-throughput platforms are also still doing well and offer an excellent entry point into sequencing. New-to-Illumina customers made up over 1/3 of shipments in Q1, which further expands our installed base and drives sequencing adoption across a wide customer network. Now on to our markets. Sequencing consumables for oncology testing climbed almost 20% year-over-year, as we keep working to democratize sequencing in this vital area of health care; during March, we obtained CE-IVD approval for TruSight Oncology Comprehensive in Europe. This novel in vitro diagnostic comprehensive genomic profiling kit is the first distributed IVD covering both DNA and RNA. TSO Comp IVD covers many mutations and biomarkers that align with European Society for Medical Oncology guidelines, which boosts the odds of extracting actionable insights from every patient biopsy. The early feedback and enthusiasm we've gotten from customers across the EU has pleased us, and we're eager to launch TSO Comp IVD in more markets, including Japan, where we filed for regulatory approval not long ago. With the TSO Comp IVD offering, we'll build on the huge worldwide growth TSO 500 is enjoying — it climbed almost 120% year-over-year during Q1. Also on the oncology side, interest keeps growing among both customers and providers for Galleri, GRAIL's groundbreaking blood test for multi-cancer early detection. Right now, more than 2,400 physicians with prescribing privileges have placed orders for Galleri, and 34 partnerships have been established by GRAIL with health systems, employers, and insurers that are investing in multi-cancer early detection to improve outcomes. Among these is GRAIL's recent collaboration with Point32Health, the entity created by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. GRAIL's first collaboration ever with a commercial health plan in the United States is Point32's two-phase pilot of Galleri. Only a week ago, GRAIL additionally announced a multiyear partnership with Munich Re Life US, enabling Galleri to be offered as part of Munich Re's effort to further early detection and treatment of cancer. Together, Munich Re and GRAIL will work to let carriers and distributors make Galleri available to current policyholders at high risk of cancer, like people who are 50 and older. On top of that, the NHS Galleri trial keeps moving forward, having enrolled over 90,000 of the 140,000 participants it plans to include. To keep up with the growing interest in Galleri and to push their R&D work further, the GRAIL team has nearly doubled over the last 8 months, now at more than 850 employees, with close to another 250 roles still open. Going forward, GRAIL intends to grow its current sales force for Galleri to strengthen launch momentum and keep driving market adoption. Now to our other markets. Our genetic disease testing business just delivered another quarter with record-setting results, driven by efforts to expand both access to and adoption of whole genome sequencing, or WGS, worldwide. Within the United States, critically ill newborns in three states — California, Oregon, and Maryland — are now able to receive WGS via Medicaid, extending coverage to an additional 17 million people. Additionally, last week brought word of a partnership with Germany's Hannover Medical School aimed at deploying WGS for seriously ill children who may have a rare or genetic condition. That initiative, similar to what we've done alongside other pediatric hospitals around the globe, illustrates how WGS can help make diagnoses and treatments happen sooner for young patients in neonatal and pediatric intensive care units. When it comes to reproductive health, the picture keeps improving on the coverage, reimbursement, and evidence-generation fronts, particularly in Europe. Noninvasive prenatal testing, or NIPT, now has broader coverage in both Spain and Italy, and Germany is likely to follow suit before the year is out. Over in infectious disease and microbiology, we posted our best quarter ever, with worldwide spending on identifying pathogens, tracking them, and tackling resistance climbing step by step. COVID monitoring was the main engine behind that, but we're seeing traction with additional pathogens too, tuberculosis among them. Back in March, the Milken Institute called on a coalition of stakeholders from multiple sectors to collaborate around data, insights, and responses targeting early disease outbreaks. During that same month, the World Health Organization introduced a 10-year plan aimed at using genomics for pan-pathogen surveillance across the globe, reflecting a widening shift toward monitoring a broader range of pathogens. Consider FIND, a diagnostics alliance with a global footprint and headquarters in Geneva. FIND launched Seq&Treat, an international initiative that deploys sequencing against drug-resistant tuberculosis, an illness that affects nearly 0.5 million people worldwide each year. Through our company, instruments are being provided so that Seq&Treat can accelerate discovery for the half of drug-resistant tuberculosis patients who currently do not achieve successful treatment. Over in our Research and Applied markets, genomic research keeps widening into more applications and more disease states. Budgets for labs — NGS specifically — are on the rise, with academic labs up roughly 9.5% and pharma and industry labs up roughly 14%. To help genomic research grow, we recently teamed up with Allelica, giving our customers state-of-the-art polygenic risk score digital tools. Thanks to Allelica's software, researchers can do a better job pinpointing people whose genetic susceptibility to life-threatening diseases is high. Still on the research side, rising use of and appetite for multiomics — proteomics especially — is fueling sequencing growth and opening opportunities. Things are going well with SomaLogic — we're working together to build a proteomics assay that combines high plexity, high sensitivity, and high specificity. Both sides are excited to help unlock the next wave of discoveries. Another space that's changing fast is the way multiomic and genomic information get combined in drug development and clinical trials. More than $123 billion gets spent each year on R&D for drug development, yet better than 90% of the drugs that enter Phase I clinical trials never reach clinical approval — fewer than 70 make it to market every year. A big driver of that high failure rate is target selection. When genomic-based approaches are used, success rates can more than double, and the cost and time needed to reach the market drop sharply. Right now, more than 85% of the human proteome has no available pharmacological approach, so we're very excited to support discovery that starts with genetics, along with new drug modalities that could substantially expand how many therapeutic targets are possible. In addition to what we're doing with Nashville Biosciences, we shared news today about a partnership with Deerfield Management. This kind of collaboration hasn't existed before: it brings together Illumina's discovery approach, which is led by genetics and AI, and Deerfield's expertise in preclinical and clinical development. Our joint intention is to convert genetic findings into novel treatments for diseases where medical needs remain unmet, and to produce a step change in the speed and efficiency of drug development. In the end, that means more patients can reach therapies that may transform their lives. We recently shared news about a partnership with Janssen aimed at accelerating the creation of precision medicines. This effort involves building companion diagnostics using our new TSO Comp IVD, as well as investigating discovery and research work on drug and biomarker targets spanning various disease areas. Such alliances are among what we anticipate will become numerous strategic collaborations with pharmaceutical companies, leveraging Illumina's capabilities to deliver precision medicine on a broad scale. Overall, our first quarter results left us encouraged, with sequencing instruments rising 20% and orders for sequencing consumables exceeding $1 billion for the very first time. With our installed base expanding considerably and a record backlog as we closed out the quarter, we've set the stage for our business to keep speeding up over the next several quarters. I'm also truly excited about the work we're doing together with our collaboration partners. Those efforts underpin the progress we continue to make in pushing sequencing forward for the good of human health. With that, I'll pass it to Sam, who'll take you through the finer points of our results and outlook. Sam?

Sam Samad

executive
#3

Francis, thanks. Just so everyone's clear, GRAIL's consolidated financials are included in what we're reporting for Q1. My plan is to walk through those consolidated numbers first, then cover how each segment — core Illumina and GRAIL — performed, and wrap up with what we're expecting for 2022. Everything I'm about to cite is non-GAAP, and that includes stock-based compensation. You can find the GAAP reconciliation for these non-GAAP figures in today's release as well as in the supplementary data posted on our website. Turning to the quarter, revenue hit a record $1.223 billion, which represents 12% growth compared with the same period a year ago. Driving that was a 20% increase in core Illumina sequencing instruments and a 13% increase in sequencing consumables. On the consumables side, growth was steady across both clinical and research, with each of those market segments climbing by double digits. For the quarter, GAAP net income came to $86 million, which works out to $0.55 per diluted share. Non-GAAP net income was $169 million, or $1.07 per diluted share, and that figure includes dilution tied to GRAIL's non-GAAP operating loss of $134 million for the quarter. Our non-GAAP tax rate was 17.8%, a drop of 250 basis points compared with a year earlier, largely driven by tax expense we recognized in Q1 2021 on earnings of certain foreign subsidiaries that are no longer indefinitely reinvested. Looking at the rise in the non-GAAP tax rate from Q4 2021 on a sequential basis, that was mostly due to the impact of R&D expense capitalization requirements put in place by the Tax Cuts and Jobs Act of 2017. For the quarter, our weighted average diluted share count stood at roughly 159 million. Now for how each segment performed. Starting with core Illumina's numbers: revenue there climbed 12% compared with the same period last year, reaching $1.221 billion. Within that, sequencing consumables for core Illumina grew 13% year-over-year to $784 million, fueled by an expanding NovaSeq installed base spanning clinical and research markets. Core Illumina's sequencing instruments revenue set a fresh record, gaining 20% versus a year ago to $212 million. The driver was yet another all-time-high quarter for NovaSeq system shipments, powered by mounting demand from oncology testing, which represented nearly 40% of NovaSeq shipments in the quarter; meanwhile, NextSeq 1000/2000 continued to draw robust interest from customers new to Illumina, and those buyers made up over 1/3 of shipments during the quarter. In Q1, our COVID-19 monitoring efforts brought in roughly $53 million from sequencing consumables and an extra $7 million from instruments, reflecting our ongoing commitment to pathogen surveillance. Revenue from core Illumina sequencing services and other sources reached $111 million, a modest increase from the same period last year, fueled by more instrument service contracts. Now for core Illumina's regional performance. The Americas brought in $646 million, a 15% rise over the prior-year period. This growth was mainly due to three key drivers: one, ongoing sample increases in oncology therapy selection; two, newer applications like single cell and proteomics; and three, pathogen surveillance programs. In EMEA, we brought in $316 million in revenue, which is 4% growth compared to a year ago. That came from momentum in both clinical end markets and emerging markets, though it was partly offset by the UK Biobank program wrapping up in the third quarter of 2021, which we had anticipated. Lower shipments into Russia stemming from the war in Ukraine had a modest effect on EMEA's growth. Greater China brought in $127 million, flat versus a year ago, since strong clinical demand in hospitals there was canceled out by COVID-19 restrictions that started in March. Turning to APJ, its revenue reached $132 million, a 33% year-over-year gain, fueled by stronger-than-anticipated expansion in large-scale research programs, oncology and genetic disease testing, and pathogen surveillance efforts. Moving now to the rest of the core Illumina P&L lines. Core Illumina non-GAAP gross margin landed at 70.2%, a 30 basis point decline versus last year, driven primarily by higher freight expenses stemming from wider strains throughout the global supply chain. Core Illumina non-GAAP operating expenses totaled $505 million, which is $85 million more than the prior year, mostly reflecting an expanded workforce along with the R&D and operations investments we are making to sustain our business's growth and scale. Despite that rise compared with a year earlier, first-quarter non-GAAP core Illumina operating expenses landed roughly $15 million under our forecast, since we hired more slowly and project spending slipped into the second quarter. Now to GRAIL's financial results. Revenue at GRAIL during the quarter reached $10 million, largely driven by fees for the Galleri test. Non-GAAP operating expenses at GRAIL totaled $139 million for the quarter, mostly stemming from costs related to head count and clinical trials. Those GRAIL non-GAAP operating expenses were about $15 million beneath our expectations, as spending moved into the second quarter. Let's move on to consolidated cash flow and balance sheet items. Operations generated $172 million in cash flow. Our days sales outstanding came in at 46 days, compared with 49 days during the prior quarter. Capital expenditures for the first quarter of 2022 totaled $61 million, free cash flow reached $111 million, and no common stock was bought back during that period; we ended the quarter holding roughly $1.4 billion across cash, cash equivalents and short-term investments. Turning now to our 2022 guidance; we continue to anticipate consolidated revenue growth between 14% and 16% for 2022, a figure that encompasses core Illumina revenue growth of 13% to 15% along with GRAIL revenue of $70 million to $90 million. We also continue to anticipate non-GAAP earnings per diluted share within the range of $4 to $4.20, a range that reflects dilution from GRAIL of $3.75, matching what we communicated earlier. For the whole of 2022, every other piece of financial guidance we gave back in February still stands. The one change is our consolidated non-GAAP tax rate, which we now anticipate landing at about 18%. In shaping our 2022 outlook, we're assuming China's lockdowns let up by June and that our China business bounces back during the latter half of 2022. Turning to Q2 2022, we expect consolidated revenue to grow 7% to 9% over the same quarter in 2021. That number factors in a roughly 300 basis point drag on total revenue growth from the COVID-related shutdowns going on in China right now. At the same time, consolidated non-GAAP gross margin should be about flat versus Q1 2022 on a quarter-over-quarter basis. On the consolidated non-GAAP operating margin side, our outlook is roughly 10%, and that represents a drop versus the first quarter of 2022 on a sequential basis. The primary drivers are a $60 million uptick in core Illumina operating expenses, plus a $25 million bump in GRAIL operating expenses. Why are those costs climbing? Mostly it comes down to the typical seasonal lift we see in compensation-related expenses — that covers our merit increase cycle — as well as the timing of hiring and project spending shifting into Q2 instead of Q1, and GRAIL's operating expenses continuing to build. When we look at core Illumina specifically, we're projecting a non-GAAP operating margin of about 23% for Q2. As for the consolidated non-GAAP tax rate in the second quarter, we expect it to come in at roughly 18%, consistent with what we've guided for the full year 2022. And that brings us to the end. On a diluted basis, share count ought to come in around where we pointed for the whole of 2022 — roughly 159 million shares. With that, I'll hand things back over to Francis, who has some final remarks.

Francis deSouza

executive
#4

Thank you, Sam. When we think about what's ahead, the core drivers of our business are still quite robust. Our installed base keeps expanding, we closed Q1 with a record backlog, and volumes are climbing as customers take on sequencing applications of greater intensity — all of which point to solid growth down the road, particularly during the back half of this year. On top of that, we keep widening access and bringing breakthrough genomic innovations to market. Our innovation pipeline is moving forward, with momentum and enthusiasm gathering behind Chemistry X, which is a breakthrough, along with our Infinity long-read technology and our NovaSeq Dx platform. Updates on all of these will come in the months ahead, and we can't wait to greet thousands of customers from every corner of the globe at the Illumina Genomics Forum toward the end of September. In addition, we'd be delighted to have you with us this autumn for our Investor Day, set for Monday, October 3, in San Diego, right after the Illumina Genomics Forum. More specifics will be shared over the next few days. Throughout our operations worldwide, we stand at the leading edge of genomics in health care. It's thrilling to roll out new technologies, work alongside pioneering partners, advocate for patient access, and back remarkable researchers and clinicians globally as together we unlock the potential of genomics to improve human health. At this point I'll ask the operator to begin Q&A.

Dan Brennan

analyst
#5

Perhaps I could begin with a two-part question for Francis and Sam. The first part concerns China, which accounts for 10% of your revenues, and you mentioned a headwind during Q2. Could you give us a picture of what happened there in Q1? It came in flat, which clearly represents a sizable slowdown. I'm just curious how much China actually subtracted from what you had anticipated in 1Q. The second part relates to NGS instruments and consumables. You're essentially keeping all of your guidance figures intact. My understanding is that you were anticipating roughly 10% growth on instruments and, as I recall, 18% growth on consumables for the full year. You clearly came in above that on instruments during Q1, while falling short of it on consumables. So please take us through, especially regarding consumables, how the year will unfold, and whether 1Q was affected, either by China or by something else. Then the last part is simply about AGBT. Presumably, we'll receive the Infinity update there. Will there be anything new disclosed on Chemistry X, or will that have to wait until the fall?

Sam Samad

executive
#6

Dan, I appreciate the questions. This is Sam speaking. I'll take the first 2 questions, then hand things over to Francis for the AGBT one. Regarding China, the figure came in at roughly $10 million below what we had expected during Q1, and that was entirely the result of the restrictions we encountered in March. As you're aware, during March we saw truly extensive — substantial restrictions across Shanghai, essentially closing down the entire city; beyond that, we also encountered restrictions in quite a few other cities. That showed up as roughly a $10 million shortfall in Q1. As we've indicated, during Q2 we anticipate a 300 basis points headwind affecting overall company growth in China; so taking it altogether, I'd describe the first half as carrying roughly a $45 million headwind for China on our results. That said, we anticipate that come June, the restrictions will begin to loosen. We're already observing encouraging signs in Shanghai. In Beijing, I believe mass testing is underway. So naturally we're staying closely attuned to the situation. Still, we're hopeful that as June arrives and afterward, things will begin to loosen. Demand fundamentals in China remain very robust. Our backlog has grown as we head into Q2. It stands above the prior 2 quarters. We've brought in new hospitals, close to 38 hospitals added to our installed base; we're deepening our penetration within hospitals. The issue really comes down to restrictions and being able to deliver products to customers given that shutdowns are occurring. As for your second question regarding instruments and consumables, yes, we got off to a very strong start this year on instruments, with growth above 20%. At the start of the year, we told everyone instruments would be less weighted toward the back half. We expect a solid beginning. Things should be more evenly spread quarter to quarter on the instrument side, so our 10% growth guidance still stands. Our backlog was quite robust, and that remains true as we enter Q1. Essentially, we're shipping and delivering against that backlog, which you saw reflected in our strong Q1 results. Turning to consumables, they outperformed what we anticipated in Q1. Growth came in at 13%. They beat our Q1 expectations, even factoring in China's effect. When you consider Q1, remember certain items from Q1 last year held back that 13% growth. Normalizing for those — for example, the UK Biobank, a $20 million benefit in Q1 of '21, plus some stocking in Q1 of '21 that was also roughly a $20 million one-time impact — consumables would have risen in the high teens. So our confidence remains high in the 18% consumables guidance for the entire year. Over to Francis.

Francis deSouza

executive
#7

Absolutely, Dan — I’ll address the inquiries regarding Chemistry X and Infinity. Both teams are advancing quite nicely. When it comes to Infinity, our approach will be to release additional customer data as the year continues and the launch gets nearer. As for Chemistry X, there will definitely be far more details shared at the customer event, and also at the investor event; in the meantime, if any fresh material data becomes available to present, we’ll make it public.

Dan Arias

analyst
#8

Francis, perhaps on a comparable theme — along similar lines. Last quarter you noted the backlog stood at twice what it was the year before, and now you're describing it here as being at record highs; so it stands to reason the backlog increased during the quarter. Would that be accurate? Then regarding the NovaSeq pull-through rate, I'm simply wondering if you landed within the range you'd been targeting for the year, or whether the events in March pushed you somewhat under it, making it merely a question of returning to that range later in the year; and then, if I may, on GRAIL, is there anything fresh concerning the European Commission and the timing tied to news about that process?

Sam Samad

executive
#9

Yes. Perhaps I can step in there, Dan, and address the first one about backlog. So we've discussed the reality that instrument backlog reached a record as we entered Q1. It was twice the backlog we had at the start of last year. As for overall backlog, that too hit a record in Q1. So let's be clear about what makes it up; so we had record overall backlog in Q1, or as we exited Q1. So without question, the overall backlog did grow, though I think the doubling was really more about the instrument backlog. So as for NovaSeq pull-through, allow me to carry on with that. So we continue to expect pull-through to fall within the range of 1.2% to 1.3%. So we expect that as we get — first of all, our placements for NovaSeq have been unbelievably strong. Q1 was a record shipment quarter for NovaSeq. As we get more and more installed base expansion and we get more shipments into NovaSeq, as you know, it's going to take — typically, those customers need about a quarter or 2 before they ramp up to their usual pull-through, but we have every confidence that we're still going to be in the — in that 1.2% to 1.3% pull-through range for the year.

Francis deSouza

executive
#10

Now, regarding the question about GRAIL and where things stand with the European Commission on timing — as you're aware, there are 2 tracks we're involved in across Europe. The first involves the European Commission and its Phase II review. Our engagement with them is ongoing. While we collaborate with them to explore whether remedies might allow this deal to be approved, the clock has been stopped, and we anticipate a ruling on that either later in Q2 or during Q3. Additionally, we're involved with the EU General Court as it examines the jurisdiction of the European Commission over this deal, and we likewise expect a decision on that to arrive either later in Q2 or early Q3.

Michael Ryskin

analyst
#11

Mike Ryskin here, filling in for Derik. I'd like to dig deeper into how strong the instrument business was this quarter. Once again, a genuinely impressive outcome following a robust 2021. As you're surely aware, more and more product launches keep arriving in this space from various competitors. A few have already hit the market, while others are rolling out more or less right now. So my question is, has any of that come up when you talk with potential buyers? Are you going head-to-head with any of them more often? Does it surface during pricing discussions, or with some kind of signed agreement or similar situation? I'm curious whether it has affected margin, particularly within the mid-throughput portion of the portfolio.

Francis deSouza

executive
#12

Yes. Let me begin by saying that, on the whole, we see the genomics market as one that is both large and expanding, and we are only at the very start of tapping into it; therefore, just as we have witnessed previously, and will keep witnessing, there is space for several participants to grow within this market. And we anticipate that remaining the case for many years ahead. The buyers we serve rank among the finest and most talented anywhere; they clearly know what choices exist, and those discussions do happen. Consequently, every one of our customers, in my view, is extremely well versed in the current state of the genomics landscape, which companies are present, what lies ahead and what each vendor can be expected to deliver. So those topics definitely come up in those conversations. Still, the momentum shows in the figures we reported, correct? You observed the 20% growth during Q1. You observed the robust orders and robust shipments. You notice the momentum especially in segments such as NovaSeq, for instance, which gave us a record year during the prior year. We achieved a record Q1 when it came to shipments. And that remains the case because, whether we're talking about the top portion of the portfolio, the NextSeq line, or perhaps the lower end of the portfolio. We keep delivering a better value proposition that satisfies what customers need regarding total cost of ownership, regarding performance, regarding price points; and honestly, that is the task we must keep performing. Keep winning our customers' business by ensuring that this remains the case.

Tejas Savant

analyst
#13

Francis, I've got two questions — one about GRAIL, and one about competition, much like the earlier one there. So you brought in roughly $10 million in revenue. At the midpoint, you still expect around $80 million from GRAIL, which means a pretty steep climb over the remaining part of the year. Could you shed some light on the uptake rate you're assuming among the patient population for Galleri, in terms of the health system and employer partners you have now? Then on competition, some newer rivals have emerged. You mentioned price points in the mid-single digits per G on the medium throughput instruments. When you look at the premium portion of your lineup, in that hundred-to-two-hundred-dollar range for each genome, do you figure there's still space to come down? Or do the distinctions you offer on various other attributes keep you so well positioned that buyers continue choosing you above alternatives?

Francis deSouza

executive
#14

Absolutely — allow me to address these separately, and I appreciate you raising them. Our performance with GRAIL is something we feel good about. When we look at what they accomplished in the first quarter, it wasn't only the $10 million of revenue — it was also the progress they made on several fronts. The count of prescribing physicians grew to 2,400, and the number of partners spanning health systems, employers and insurers rose to as many as 34. They remain on track to hit the revenue outlook we set out at the start of the year, which is $70 million to $90 million. Another thing they've put in place that we know will pay off during this year and certainly beyond is getting the first commercial insurance provider in the U.S. signed up, with Point32. This is going to be thrilling on multiple fronts — as an employer, and as one of their customers, since they plan to launch it within their own organization first. And then, clearly, as they extend it out to the people they serve. Another piece of exciting news: they brought on board their very first life insurance partner, and we view that deal with Munich Re as a promising first step into a space where we believe GRAIL has substantial opportunity ahead. So there's solid momentum there. Looking a bit further out, we're also encouraged by how GRAIL's NHS study is progressing — enrollment has reached 90,000 participants now. As you may remember, there was a goal of 140,000, so they're moving along nicely, and that takes us nearer to the NHS's subsequent stage, which would involve extending this to a million individuals across the U.K. So things are going well on all fronts. I believe we're positioned to fulfill the strategy we set forth at the start of the year. Regarding the competitive environment, we think there remains ample opportunity for expansion on our part in a number of ways. First, whenever we speak with our customers, their focus is on a system's total cost of ownership; the price per G is therefore just one piece of that equation, and you also need to consider items such as the compute infrastructure; take what we offer with the NextSeqs, for instance, or the NovaSeqs — that goes far beyond core sequencing alone. The instruments come with sophisticated compute built right in, featuring FPGA arrays, whereas with other sequencers you would need to purchase that kind of compute separately. On top of that, we include capabilities such as lossless data compression algorithms. Certain customers are able to see a 5x cut in how much data needs to be stored. That represents yet another element of the TCO calculation that customers weigh when they set our systems against comparator systems. So the price per G is only one piece of the equation. Once you factor in all those additional elements, it becomes clear just how strong the value is that you receive from Illumina. That said, we also enjoy considerable room to keep pushing the price per G lower. You've often heard us discuss the innovations sitting in our pipeline and the sort of headroom that provides going forward, both for new instruments and possibly for existing product lines as well; so we clearly have plenty of gas in both of those tanks, correct? One is the end-to-end TCO comparison, where our proposition is very strong, and the other is taking every one of the components and continuing to bring the price down through technological innovation that places us on dramatically new S-curves.

Kyle Mikson

analyst
#15

Nice work on the quarter. It's good to know that we'll get more detail soon on the upcoming products, both by ear and by eye. That said, on the Chemistry X economics, when exactly do you plan to share some color? And to set a baseline, was a price cut of 20% to 25% what you initially had in mind — that being 20% to 25%? Moving to my second question, on GRAIL. I get that biopharma plus MRD collaboration revenue makes up a piece of the GRAIL revenue guidance. However, when it comes to Galleri revenue in particular, is the guidance built on mostly clinical trial revenue, as you were sort of describing, Francis — NHS SUMMIT trial, and so forth — or on actual clinical diagnostic revenue, such as Intermountain alignment, and so forth?

Francis deSouza

executive
#16

Fine; let's handle these one by one. On Chemistry X, technical updates will keep coming your way as they're ready. As for the economics, that update really hinges on which instrument we place Chemistry X into, since it will differ, because in the end an instrument's economics rest on the new chemistry but equally on all the other components of that instrument, correct? The optics included, the flow cells included, the compute infrastructure; therefore Chemistry X will certainly be a major driver of better economics in an instrument, yet to tell you the economics overall, we would need to detail the full configuration of an instrument, and after that we'll tell you what that instrument delivers. What I can say at this moment is that, honestly, 20% to 25% would be on the low side. Consider the road map for the new chemistry, all right? Think about what the prior generation of chemistry delivered, all right? When Solexa arrived in 2007, the project we received from them carried a $150,000 launch price — for one genome. At present, that figure is under $600, correct? So that chemistry — considering its lifetime — well, I don't want to attribute everything to the chemistry alone, since clearly there were innovations, once again, in optics and data paths and compute and all things tied to that. Still, an extremely, extremely substantial road map when it comes to price reductions that became possible. Thus this marks the biggest chemistry update we've made since SBS was first invented. Consequently, you ought to view the lifetime of this chemistry as providing considerable headroom on performance, and on price reduction as well. So personally, I'd feel let down if, across this chemistry's lifetime, you were only contemplating a reduction of 20% to 25%. Now, secondly, let's discuss GRAIL. Regarding GRAIL revenue this year, what we stated and would restate is that testing will account for the bulk of GRAIL revenue this year. A portion of it will stem from the partnerships they have in pharma, though that portion won't make up most of what they bring in. And that is the goal they're pursuing under the strategy they've got in place.

David Westenberg

analyst
#17

Regarding cost per G and competition, I know I might sound like a broken record, yet it didn't address my particular idea, reasoning, or inquiry. That topic would be that mid-throughput is certainly packed. You've spoken extensively regarding the competitive levers available to you there. Speaking of the high-throughput sector, if someone matches your price per G or even exceeds it, how at ease are you that within high-throughput, a rival launch wouldn't harm you too much? Also, ought we to cite BGI as an illustration? I'm hoping this next one is brief for my follow-up with Sam. Namely, many cancer labs producing cash flow are currently reducing costs. During that belt-tightening, has discussion about purchasing sequencing instruments arisen?

Francis deSouza

executive
#18

Excellent. Thanks for asking. I'll begin with the initial one — competing within high-throughput has always been necessary for us, and we anticipate doing so going forward. To start, as I mentioned before, the genomics sector overall is sizable and expanding, still early in terms of adoption. Consequently, we anticipate new vendors appearing, and some existing ones possibly exiting. Competition in that area seems likely, and our plans account for it. That said, I feel quite assured about our competitive standing there right now, and I'm incredibly thrilled about our road map for strengthening that standing. Let me repeat what I noted a bit ago — even considering only cost, looking at total cost of ownership matters greatly, particularly for high-throughput. Producing such large volumes of data means compute expenses, storage expenses, and end-to-end workflow expenses all grow quite significant. Thus, considering our innovation levers, which aren't limited to pushing performance and pricing for core sequencing but also include end-to-end workflow, we can deliver an outstanding value proposition within high-throughput. Now, the second inquiry concerns reducing costs.

Sam Samad

executive
#19

Yes. So Dave, thank you for asking that. The brief response is negative, though I want to walk through the reasoning behind why it isn't true that any trimming of expenses related to sequencing is occurring. When you consider the set of clients we serve, roughly 8,000 accounts make up an extremely varied group. Yet if you look at commercial labs and clinical clients, sequencing plays a role in generating their income. Thus, essentially the entire pull comes from the end markets. And what actually fuels it is the requirement for testing, plus the reality that we observe quite strong demand, which stems from solid reimbursement, market access and utilization in areas such as oncology or genetic disease testing. So no, we aren't observing any deceleration caused by expense reductions, since I believe end demand is what truly drives things. Turning to the research side, funding into the research market remains very robust, whether that's once more toward research in oncology, research in genetic disease, or research in pathogen surveillance and other initiatives. So I think the brief response would be negative, though I hope this provides a bit of color as to why.

Puneet Souda

analyst
#20

Francis, from what you're describing regarding Chemistry X and what the new instrument might potentially be able to pull out of Chemistry X, I mean, this ought to get you to a $100 genome and considerably past that. So could you discuss which applications will begin to become available given the reduction that is substantially greater than 25% — the sort of reductions you're referring to? And what impact does that have on the — perhaps what impact does that have on the diagnostic mix of your customers over the longer term too? I believe they're running at close to 50% of sequencing consumables. So perhaps just help us grasp the applications and where diagnostic customers are able to participate. Just a brief follow-up with Sam. What was the pricing contribution during the quarter — how much did pricing add in the quarter? And what ought we to anticipate it will do for the year within the guidance?

Francis deSouza

executive
#21

Yes, Puneet. A great deal can become available as we keep pushing the sequencing price lower, since the truth today is that we remain at quite an early point in grasping how a genome maps to human health and human disease; we've opened up the initial clinical applications, NIPT cancer therapy selection. There are a great many more that we're confident will appear once we can perform the experiments at the scale we require; for instance, if you consider complex diseases such as neurological conditions, be it autism or schizophrenia or Alzheimer's or Parkinson's, what the research community tells us is that if you examine schizophrenia, for instance, within families, it's evident there's a genomic element to it, yet the causality involved is complex. And the sole means of deciphering the biology is to run cohorts that aren't counted in thousands or even tens of thousands, but are considerably larger than that. And so there's enormous promise to reveal and tackle some of the genomic roots of neurological conditions, but we require cohorts far, far larger than what has been seen historically. And that's — those are the sorts of experiments. Likewise, when you consider what we must grasp about single cells and the heterogeneity of expression throughout the cells — throughout the human body, there are tens of trillions of cells within the body. So if you wish to conduct even merely a representative — statistically representative experiment, you don't require just thousands of cells the way people do today, you require sizes in the millions or tens of millions, and we must grasp that. And so those are the sorts of experiments that we're being pushed on and told, okay, if you can simply keep pushing the prices lower, it just unlocks the large research areas which will subsequently translate into a future area of new diagnostics, new screening modalities along with new therapeutics. So those represent the types of really, really large markets that become available. Right now, when considering the 10 leading mortality causes for humanity, cancer is among those top 10, and genomics contributes to tackling it. The truth is, as you extend this out 10 years, possibly more, genomics will assist us in tackling every one of those 10. However, to genuinely grasp the biology, a tremendous volume of research must be carried out. And beyond that, we require a completely novel array of diagnostic screens along with therapeutics; that is what becomes possible.

Sam Samad

executive
#22

Yeah. And Puneet, I appreciate you asking about pricing. Let me just take you through our usual approach — this is exactly what happened in Q1, and it lines up very well with how we've handled things in prior years. Typically, on certain products — not the entire portfolio — we implement what I'd describe as a low single-digit price bump. It's primarily applied on the reagent side, and on library prep as well. And like I mentioned, it falls in the low single digit; that's fully in line with our annual practice. So there is some effect across the full year. It's factored into the guidance we provided; yet there's nothing out of the ordinary relative to previous years. We haven't implemented any notable inflationary price hike that got pushed through to our customers. We haven't raised freight charges at this stage. So what we've carried out is our standard Q1 price increase.

Patrick Donnelly

analyst
#23

Patrick, I’ll take the one about the clinical market. Clearly, momentum keeps building there, with really impressive figures. Could you discuss where you’re observing the greatest underlying strength? And then, clearly, you mentioned the competition a bit. How confident are you in your positioning there, as perhaps more players pursue the clinical side?

Francis deSouza

executive
#24

Yes. We’re witnessing genuine strength everywhere in the clinical market. So across geographies, we’re seeing an enormous degree of strength, clearly, in the Americas and so forth. Yet even in China, where we discussed the COVID restrictions, we still maintained robust momentum in the clinical market and signed up, as Sam noted, 38 new hospitals too. So what’s fueling that? Among the largest drivers is oncology testing for therapy selection. The reimbursement that has been established for that, the shift from smaller panels to comprehensive genomic profiling, which calls for larger panels. Now people are considering clinical exomes, and that’s generating an enormous degree of strength. And when you examine several of our metrics, whether it’s the consumables being drawn into that market or even the NovaSeqs, we observed, for instance, I believe it was roughly 40% of our NovaSeqs shipped in Q1 went to oncology testing customers. So I’d begin by saying oncology testing for therapy selection is a juggernaut that powered much of our growth in the clinical markets last year. It’s still unfolding this year because many of the underlying demand drivers remain strong. We also observed, however, robust demand in genetic disease testing, and that delivered another strong quarter in Q1. And some comparable dynamics are at play there. The dramatic expansion in coverage over the last couple of years is truly helping drive that demand. Furthermore, those applications are sequencing-intensive applications. So you’re referring to clinical whole genomes, you’re referring to trios where those are available. And so that keeps fueling some of the demand in the clinical markets that we’re seeing. And there’s considerable headroom ahead in both of those markets. The clinical market actually is a 1 market — is a market where, I believe, we possess a special strength, correct? Because we have built, over the last decade, a number of things that customers truly appreciate; so for instance, we have cleared boxes, both the MiSeqDx, which received clearance in 2013, but also now we have the NextSeq Dx that’s available to customers, and we are progressing along the path to deliver a NovaSeq Dx. That places us in a unique position at this point: if you wish to develop on a cleared box, we are a really excellent choice for you. Beyond that, there are certain end-to-end workflows our customers find genuinely thrilling. TSO 500 is an outstanding offering, and as we mentioned, when you examine Q1, TSO 500 experienced exceptionally robust expansion — climbing beyond 100% versus the same quarter a year earlier. On top of that, demand keeps building for our VeriSeq NIPT end-to-end workflow. That places us, once again, in a particularly strong position relative to any other party customers might consider — specifically, buyers seeking cleared workflows they can purchase and put to use. And even those customers operating in LDT mode have invested considerable time creating their own validated workflows on our instruments, including when those instruments are our non-DX ones, yet building those validated workflows up and scaling them has required a great deal of time. From where they stand, then, continuing to grow their relationship with Illumina is simply the preferable route for running their laboratories. Those are a few of the dynamics at play in that area.

Vijay Kumar

analyst
#25

Just one question, Sam, about the 2Q guidance. At the midpoint, even if you strip out the 300 basis point hit from China lockdowns, I believe that leaves $1.25 billion, which sits below what Street models have. Could you discuss any cadence problems? Is this a comp problem or a Street modeling problem? Please address the 2Q guide. Then I have a follow-up about supply chain — during Q1, earnings came in, as I recall, 19% above Street models. Is there any cadence problem with expenses, or incremental supply chain pressures that this guide incorporates given how strong Q1 was?

Sam Samad

executive
#26

Yes. Regarding Q2, Vijay, thank you for asking. The key point, I'd say, is that yes, growth takes a 300 basis point hit from China. Growth in Q2 year-over-year also faces another hit that I don't believe you're including, which is that during Q2 of 2021, we received a onetime benefit from an NIPT settlement. That amounted to $20 million. So growth is affected by that too; that's a year-over-year effect, though, not a sequential one, which I think was your separate question about whether anything shows up sequentially. Nothing specific comes to mind besides the fact that, sequentially, China clearly represents a $35 million negative impact in Q2. We remain very confident in the guide we've provided, along with the second half momentum we anticipate. And again, I'd note, looking at Q2, there's also the UK Biobank noise, which we will lap at the end of Q3. As for your supply chain question and whether it has any effect, listen, supply chain is under pressure, I think, for most companies. Our guide reflects that through operating margin. Nothing incremental is what we expect in the second half. This is the first half. Looking at our operating margin profile across first half and second half, consolidated operating margins come to roughly about 14% in the first half; roughly around 17% in the second half. Part of that stems from revenues scaling up in the second half; yet despite the supply chain pressures that I think we're managing quite effectively to ensure there's no disruption and really offsetting some of the additional costs, I'd say we remain very confident about our operating margin guidance for the year and the sequential growth we see in the second half.

Luke Sergott

analyst
#27

Could you discuss how GRAIL is being adopted? I realize you've touched on this before, but aside from concierge and executive health plans, what sort of demand are you seeing from just the ordinary, everyday customer?

Francis deSouza

executive
#28

Yeah, absolutely. Beyond those areas you mentioned, we're seeing uptake from organizations such as employers. And honestly, it was unexpected, and it's thrilling to observe the variety of sectors in which employers are enrolling. So the thinking was that you'd anticipate certain early adopter sectors, perhaps tech, perhaps financial services, since those areas tend to adopt benefits sooner. So you'd figure some of those employers would show up. But the breadth of sectors that appeared was a pleasant surprise; for instance, logistics and transport businesses, media businesses. It's a wider list than you'd anticipate, and that carried on into Q1 too. They're also enrolling beyond concierge systems. They're enrolling health systems such as Point32 that we highlighted, life insurance companies such as Munich Re. And then there's definitely a retail component to what they're reaching, and through their website via their partnership with Genomic Health. And that keeps growing too. And that's likewise fueling their interest in wanting to keep expanding their profile in front of consumers. And so you ought to expect them to see more when it comes to getting the GRAIL brand and the Galleri brand in front of consumers. They're also broadening their reach directly to oncologists, and we discussed the fact that they're growing their staff. Part of that involved growing their commercial staff, their sales staff who actually call on doctors. And so that will keep growing demand, both in terms of bringing new prescribing doctors into the fold, but also continuing to expand the number of tests that a prescribing doctor orders.

John Sourbeer

analyst
#29

I've got 2 parts to ask about here, both concerning the GRAIL MRD assay. Is there anything new on possible studies or milestones ahead as we approach the 2023 launch? Then regarding Chemistry X, information has been scarce. Given the record NovaSeq backlog and the possibility of new platforms coming soon, what have customers said so far — what's the early feedback?

Francis deSouza

executive
#30

Certainly. Progress on their MRD work is ongoing within the GRAIL team; we're eager about what it will deliver to the market, bringing their hypothesis-free, tumor-naive strategy into it. In our view, that's a valuable assay for customers, letting them get tested faster than something requiring a tissue sample, for instance. So we see it as a valuable addition to the market. Right now, we have nothing further to report beyond the team's continued efforts and advancement. Once we do have something, we'll be certain to share it. Customer response to Chemistry X so far has been quite favorable, generating excitement about its potential. Of course, right now it isn't linked to any particular instrument, and there's curiosity regarding when and in what form factor they'll be able to use Chemistry X, yet overall there's enthusiasm about the promise of this new chemistry era for SBS. They've all witnessed what SBS has achieved across the last 17 years. As a result, there's tremendous excitement for the next stage of this journey. Pardon me, allow me to add that — I'll note, though — despite everything I've said, it hasn't really dampened demand, as you've seen, for our current instruments, the NextSeq 1000/2000 and the NovaSeqs; demand for those instruments remains really strong. That's since our customers know our history of taking care of them when new products arrive, you know, through offering very solid upgrade paths and reviewing what they've ordered in the backlog and ensuring they're satisfied with, how we might shift orders to new instruments, should they decide that; and so we've built, I believe, a solid record of guiding people through an upgrade process, whether that involves trade in policies. And so that record across the last decade, I think, helps customers feel confident about proceeding with instruments, aware that, insofar as we launch an instrument that upgrades any portion of our portfolio, we'll offer very solid upgrade programs for them.

Jack Meehan

analyst
#31

On GRAIL, I had three things I wanted to ask. To start, the NCI put out a blog post not long ago about testing for multiple cancers at once. Their point was that finding cancer isn't sufficient on its own — for an MCED test to matter, it has to make survival better. So, Francis, I'd like to hear how you'd respond to that. Second, what's your current thinking on when the FDA might approve Galleri? And last, how confident are you that the study is up and running and that enrollment is big enough for the FDA to grant approval?

Francis deSouza

executive
#32

Sure. Let's take all three in order. I'll begin with what the NCI wrote. Honestly, the underlying point is that in the end, you do want to see whether survival rates move; that matters, and we'll be following it across the coming years. Clearly, gathering that type of data takes a very long time. But of course we will obtain it. That said, we already understand that how well someone survives cancer varies greatly based on the stage at which it's found; yet even with something as lethal as pancreatic cancer, the odds of surviving are better when you find that pancreatic cancer at an early point rather than finding a cancer late; and cancer places such a heavy burden on the world; every year, 10 million people die of cancer, and in the U.S. alone that figure is 600,000. And since it's true that survival is more likely when the disease is caught early, we know that among those who die of cancer, 71% die from cancers that have no screens, since those type of cancers can't be caught early. And so those are the — that's the facts — the facts we have are what's driving doctors to prescribe this test for their patients. And at this point they've reached 2,400 doctors who prescribe it — keep in mind this test only became available in June. So a year ago there were 0 doctors, and today there are 2,400 doctors who feel confident and at ease prescribing this test for their patients; so I expect that number to keep growing. And as it grows, we'll keep expanding the data set so that eventually we can follow this through to survival rates. So that data will come in time; meanwhile, we think many lives will be saved along the way. The team keeps making headway in its discussions with the FDA. There are no new time lines to share. The study's size, in my view, won't be the issue. I believe it will simply require time. I believe the studies have been powered sufficiently for what they need, and our dialogue with the FDA has been constructive.

Sallilyn Schwartz

executive
#33

Excellent. We appreciate you being with us on this call. Just to note, you'll be able to find a replay in the Investors area of our site. That wraps up today's call, and we're eager to reconnect with you for our next update once our second fiscal quarter of 2022 has closed.

Operator

operator
#34

This concludes today's call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.